Insider Selling: Beta Bionics (NASDAQ:BBNX) Insider Sells $680,620.20 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 36,870 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $18.46, for a total value of $680,620.20. Following the completion of the transaction, the insider directly owned 87,157 shares in the company, valued at approximately $1,608,918.22. This trade represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hopman also recently made the following trade(s):

• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97.
• On Wednesday, June 24th, Mark Hopman sold 1,258 shares of Beta Bionics stock. The shares were sold at an average price of $15.01, for a total transaction of $18,882.58.

Beta Bionics Stock Down 0.1%

Shares of NASDAQ BBNX opened at $16.57 on Friday. The firm has a market cap of $745.48 million, a PE ratio of -10.04 and a beta of 3.37. The company’s fifty day simple moving average is $17.29 and its 200 day simple moving average is $13.80. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. On average, equities analysts predict that Beta Bionics, Inc. will post -2.1 earnings per share for the current year.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Neutral Sentiment: Reported short interest was zero as of September 10, offering no evidence that elevated short selling is driving the recent weakness; however, the figures may reflect incomplete or anomalous reporting.
• Negative Sentiment: Multiple law firms reminded shareholders of a November 3, 2026 deadline to seek lead-plaintiff status in a federal securities class action covering purchases made from July 30, 2025, through February 24, 2026. The repeated notices increase the visibility of the litigation risk, although they largely represent competing announcements about the same case. Beta Bionics class action deadline notice
• Negative Sentiment: The lawsuit alleges that Beta Bionics and certain executives misled investors about the iLet system’s safety, efficacy, and regulatory status. Claims reportedly concern an FDA Warning Letter, quality-management-system non-conformities, and allegedly undisclosed customer complaints involving potentially life-threatening hypoglycemia. These are allegations and have not been proven in court. Beta Bionics shareholder alert and allegations
• Negative Sentiment: Insider Mark Hopman sold 36,870 shares for approximately $680,620, reducing his holdings by about 29.7%. The transaction was executed under a pre-arranged Rule 10b5-1 plan, which limits—but does not eliminate—the negative signaling effect. SEC insider-sale filing

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Eventide Asset Management LLC boosted its stake in shares of Beta Bionics by 0.8% in the 4th quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock worth $152,233,000 after buying an additional 37,476 shares during the last quarter. Soleus Capital Management L.P. boosted its holdings in shares of Beta Bionics by 12.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock worth $55,622,000 after buying an additional 424,817 shares during the last quarter. BlackRock Inc. bought a new position in Beta Bionics during the second quarter valued at about $52,340,000. Vanguard Group Inc. raised its position in Beta Bionics by 213.5% in the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after acquiring an additional 1,509,217 shares during the period. Finally, Eversept Partners LP boosted its stake in Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after acquiring an additional 736,576 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms have recently commented on BBNX. Truist Financial boosted their price objective on Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Monday, July 13th. William Blair started coverage on shares of Beta Bionics in a report on Friday, August 21st. They set a “market perform” rating on the stock. Weiss Ratings upgraded shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Bank of America decreased their target price on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research report on Monday, May 18th. Finally, UBS Group initiated coverage on shares of Beta Bionics in a research report on Tuesday, July 28th. They issued a “buy” rating and a $22.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.10.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.